Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-06-21
2011-06-21
Weber, Jon P (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07964365
ABSTRACT:
Methods for measuring c-Met levels in urine and blood samples are provided. Methods for diagnosis and prognosis evaluation for cancer are also provided.
REFERENCES:
patent: WO 2005/026361 (2005-03-01), None
patent: WO 2006/056766 (2006-06-01), None
patent: WO 2007/016367 (2007-02-01), None
Dharmawardana et al. Meeting Abstract only. “Soluble c-Met ectodomain detecction in urologic malignancies” Oncogenic Pathways in Cancer, Anaheim Convention Center, Apr. 2005.
Pisters et al. “c-Met proto-oncogene expression in benign and malignant human prostate tissues”, J of Urology, 1995, 154:293-298.
Wang et al. “Alterations of APC, c-met and p53 genes in tumor tissue and serum of patients with gastric cancers”, J of Surgical Research, 2004, 120:242-248.
Joseph et al.“Expression of Scatter factor in human bladder carcinoma” J of the National Cancer Institute, 1995, 87(5):372-377.
Dharmawardana et al., “Soluble c-Met ectodomain detection in urologic malignancies,” Proceedings of the American Association for Cancer Research Annual Meeting, 2005, 46, p. 656.
Christensen et al., “A Selective Small molecule inhibitor of c-Met kinases inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo,” Cancer Research, 2003, 63(21), 7345-7355.
Wajih et al., “Vascular origin if a soluble truncated form of the hepatocyte growth factor receptor (c-Met),” Circulation Research, Grune and Stratton, 2002, 90(1), 46-52.
Christensen et al., “c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention,” Cancer Letters, 2005, 225(1), 1-26.
Parr et al., “Expression of hepatocyte growth factor/scatter factot, its' activator, inhibitors and the c-Met receptor in human cancer cells,” International Journal of Oncology, Editorial Academy of the International Juornal of Oncology, 2001, 19(4), 847-863.
Athauda et al., “c-Met ectodomain shedding rate correlates with malignant potential,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2006, 12(14), 4154-4162.
Komada et al., “Proteolytic processing of the hepatocyte growth factor/scatter factor receptor by furin,” FEBS Lettersm, 1993, 328, 25-29.
Comoglio et al., “Scatter Facotrs and invasice growth,” Seminars in Cancer Biology, 2001, 11, 153-165.
Funakoshi et al., “Hepatocyte growth factor: from diagnosis to clinical applications,” Clinic Chimica Acta, 2003, 327, 1-23.
Birchmeier et al., “Met, metastasis motility and more,” Nat. Rev. Mol. Cell. Biol., 2003, 4, 915-925.
Schmidt et al., “Scatter factor/hepatocyte growth factor is essential for liver development,” Nature, 1995, 373, 699-702.
Uehara et al., “Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor,” Nature, 1995, 373, 702-705.
Rosario et al., “How to make tubes: signalling by the met receptor tyrosine kinase,” Tends Cell Biol., 2003, 13, 328-335.
Birchmeier et al., “Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase,” Trends in Cell Biology, 1998, 8, 404-410.
Jin et al., “Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardinal infarction,” J. Pharmacol. Exp. Ther., 2003, 304, 654-660.
Huh et al., “Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair,” PNAS, 2004, 101, 4477-4482.
Liu, Y., “Hepatocyte growth factor in kidney fibrosis: therapuetic potential and mechanisms of action,” Am. J. Physil. Renal Physiol., 2004, 287, F7-16.
Furge et al., “Met receptor tyrosine kinase: enhanced signaling thourgh adapter proteins,” Oncogene, 2000, 19, 5582-5589.
Yu et al., “Frequency of TPR-MET rearrangement in patients with gastric carcinoma and in first-degree relatives,” Cancer, 2000, 88, 1801-1806.
Matsumoto et al., “Hepatocyte growth factor: renotropic role and potential therapuetics for renal diseases,” Kidney International, 2001, 59, 2023-2028.
Michalopoulos et al., “Liver regeneration,” Science, 1997, 276, 60-66.
Nakamura et al., “Myocardial protection from ischemia/reperfusion in jury by endogenous and exogenous HGF,” J. Clin. Invest., 2000, 106, 1511-1519.
Birchmeier et al., “Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells,” Ciba Found. Symp., 1997, 212, 230-240.
Pennacchietti et al., “Hypoxia promotes invasice growth by transcriptional activation of the met protooncogene,” Cancer Cell, 2003, 3, 347-361.
Stahl et al., “Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced inEscherichia coli,” Biochem J., 1997, 236, 763-772.
Tang et al., “TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression,” J. Clinical Invest., 2003, 112, 1116-1124.
Chu et al., “Genetic abnormalties specifically associated with varying metastatic potential of prostate cancer cell lines as detected by comparative genomic hybridization,” Cancer Genet Cytogenet, 2001, 127, 161-167.
Aebi et al., “cDNA structures and regulation of two interferon-induced human Mx proteins,” Mol. Cell Biol., 1989, 9, 5062-5072.
Salerno et al., “Inhibition of signal transduction by thenm23metastasis suppressor: Possible mechanisms,” Clin. Exp. Metastasis, 2003, 20(1), 3-10.
Rosen et al., “Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder,” J. Urol., 1997, 157, 72-78.
Cheng et al., “Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation,” J. Clin. Oncol., 2002, 20, 1544-1550.
Blobel, C.P., “Adams: Key Components in EGFR Signalling and Development,” Nat. Rev. Mol. Biol., 2005, 6, 32-43.
Masson et al., “Tumor necrosis factor receptor-associated periodic syndrome (TRAPS): definition, semiology, prognosis, pathogenesis, treatment, and place relative to other periodic join diseases,” Joint Bone Sprine, 2004, 71, 284-290.
Prat et al., “C-terminal truncated forms of Met, the hepatocyte growth factor receptor,” Mol. Cell. Biol., 1991, 11, 5954-5962.
Crepaldi et al., “Generation of a truncated hepatocyte growth factor receptor in the endoplasmic reticulum,” J. Biol. Chem., 1994, 269, 1750-1755.
Galvani et al., “Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form,” Biochem. Pharmacol., 1995, 50, 959-966.
Nath et al., “Shedding of c-Met is regulated by crosstalk between a G-protein couple receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloporteinase,” J. Cell. Sci., 2001, 114, 1213-1220.
Jeffers et al., “Enhanced tumorigenicity and invasion-matastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network,” Mol. Cell Biol., 1996, 16, 1115-1125.
Koochekpour et al., “Met and hepatocyte growth factor/scatter factor expression in human gliomas,” Cancer Res., 1997, 57, 5391-5398.
Santer et al., “Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells,” Breast Cancer Res. Treat., 2001, 65, 101-110.
Leone et al., “Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity,” Oncogene, 1993, 8, 2325-2333.
Burgess et al., “Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor with Therapeutic Pot
Athauda Gagani
Bottaro Donald P.
Burgess Teresa Lynn
Amgen Inc.
Shen Bin
The United States of Americam as represented by the Secretary, D
Weber Jon P
Woodcock & Washburn LLP
LandOfFree
Methods for diagnosing and monitoring the progression of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for diagnosing and monitoring the progression of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosing and monitoring the progression of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2700951